BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1991 related articles for article (PubMed ID: 18845169)

  • 1. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
    Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
    Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydrocinchonine, cinchonine, and quinidine potentiate paclitaxel-induced cytotoxicity and apoptosis via multidrug resistance reversal in MES-SA/DX5 uterine sarcoma cells.
    Lee SY; Rhee YH; Jeong SJ; Lee HJ; Lee HJ; Jung MH; Kim SH; Lee EO; Ahn KS; Ahn KS; Kim SH
    Environ Toxicol; 2011 Aug; 26(4):424-31. PubMed ID: 20196146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Euphorbiasteroid reverses P-glycoprotein-mediated multi-drug resistance in human sarcoma cell line MES-SA/Dx5.
    Choi JS; Kang NS; Min YK; Kim SH
    Phytother Res; 2010 Jul; 24(7):1042-6. PubMed ID: 19960428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
    Wang TX; Yang XH
    Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human sarcoma cell lines MES-SA and MES-SA/Dx5 as a model for multidrug resistance modulators screening.
    Wesolowska O; Paprocka M; Kozlak J; Motohashi N; Dus D; Michalak K
    Anticancer Res; 2005; 25(1A):383-9. PubMed ID: 15816562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer effects of a specific mixture of nutrients in the multidrug-resistant human uterine sarcoma MES-SA/Dx5 and the drug-sensitive MES-SA cell lines.
    Roomi MW; Kalinovsky T; Roomi NW; Rath M; Niedzwiecki A
    Oncol Rep; 2012 Jan; 27(1):17-27. PubMed ID: 21947138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of P-glycoprotein-mediated multidrug resistance in human sarcoma MES-SA/Dx-5 cells by nonsteroidal anti-inflammatory drugs.
    Angelini A; Iezzi M; Di Febbo C; Di Ilio C; Cuccurullo F; Porreca E
    Oncol Rep; 2008 Oct; 20(4):731-5. PubMed ID: 18813811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of multidrug resistance by 4-chloro-N-(3-((E)-3-(4-hydroxy-3-methoxyphenyl)acryloyl)phenyl)benzamide through the reversible inhibition of P-glycoprotein.
    Kim YK; Song YJ; Seo DW; Kang DW; Lee HY; Rhee DK; Han JW; Ahn CM; Lee S; Kim SN
    Biochem Biophys Res Commun; 2007 Mar; 355(1):136-42. PubMed ID: 17286965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The acridonecarboxamide GF120918 potently reverses P-glycoprotein-mediated resistance in human sarcoma MES-Dx5 cells.
    Traunecker HC; Stevens MC; Kerr DJ; Ferry DR
    Br J Cancer; 1999 Nov; 81(6):942-51. PubMed ID: 10576649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
    Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of multidrug resistance p-glycoprotein activity by flavonoids and honokiol in human doxorubicin- resistant sarcoma cells (MES-SA/DX-5): implications for natural sedatives as chemosensitizing agents in cancer therapy.
    Angelini A; Di Ilio C; Castellani ML; Conti P; Cuccurullo F
    J Biol Regul Homeost Agents; 2010; 24(2):197-205. PubMed ID: 20487633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel.
    Zhu X; Sui M; Fan W
    Anticancer Res; 2005; 25(3B):1953-62. PubMed ID: 16158930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
    Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
    J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
    Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
    Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysosomal accumulation of drugs in drug-sensitive MES-SA but not multidrug-resistant MES-SA/Dx5 uterine sarcoma cells.
    Wang E; Lee MD; Dunn KW
    J Cell Physiol; 2000 Aug; 184(2):263-74. PubMed ID: 10867652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel indirubin derivative PHII-7 potentiates adriamycin cytotoxicity via inhibiting P-glycoprotein expression in human breast cancer MCF-7/ADR cells.
    Shi R; Li W; Zhang X; Zhang Y; Peng H; Xie Y; Fan D; Liu R; Liu X; Xiong D
    Eur J Pharmacol; 2011 Nov; 669(1-3):38-44. PubMed ID: 21871878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CJY, an isoflavone, reverses P-glycoprotein-mediated multidrug-resistance in doxorubicin-resistant human myelogenous leukaemia (K562/DOX) cells.
    Ji BS; He L
    J Pharm Pharmacol; 2007 Jul; 59(7):1011-5. PubMed ID: 17637197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.
    Newman MJ; Rodarte JC; Benbatoul KD; Romano SJ; Zhang C; Krane S; Moran EJ; Uyeda RT; Dixon R; Guns ES; Mayer LD
    Cancer Res; 2000 Jun; 60(11):2964-72. PubMed ID: 10850444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levistolide A overcomes P-glycoprotein-mediated drug resistance in human breast carcinoma cells.
    Chen F; Wang T; Wang J; Wang ZQ; Qian M
    Acta Pharmacol Sin; 2008 Apr; 29(4):458-64. PubMed ID: 18358092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimultidrug-resistant effect and mechanism of a novel CA-4 analogue MZ3 on leukemia cells.
    Xu D; Fang L; Zhu Q; Hu Y; He Q; Yang B
    Pharmazie; 2008 Jul; 63(7):528-33. PubMed ID: 18717489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 100.